Tang Yiwen, Cai Yuyang, Ding Jiasen, Ji Ronfu, Wang Xiong, Zhang Zejia, Xu Feng, Gao Zhan
Graduate School of Beijing University of Chinese Medicine, Beijing, China.
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Med (Lausanne). 2024 Dec 27;11:1483864. doi: 10.3389/fmed.2024.1483864. eCollection 2024.
This paper aims to evaluate the disparities in efficacy and safety across various oral Chinese patent medicines for the treatment of benign prostatic hyperplasia (BPH), using a frequency-based reticulated meta-analysis.
The researchers searched the following databases: Web of Science, PubMed, Excerpta Medical Database (Embase), Cochrane Library, China Knowledge Network (CNKI), China Biomedical Literature Service System (SinoMed), Wanfang Data Knowledge Service Platform and China Science and Technology Periodicals Database (VIP). Besides, the researchers collected all randomized controlled trials (RCTs) of oral Chinese patent medicines, as well as simple preparations and simple preparations for benign prostatic hyperplasia from the establishment of the database until July1, 2024. After two researchers independently screened literature, extracted data, and evaluated the risk of bias in the included studies, a net meta-analysis was conducted using Stata 16.0 software.
Seventy-two RCTs involving 15 oral Chinese patent medicines and a total of 7,800 patients were included. Net meta-analysis manifested that "Jinkuishenqi capsule (JKSQ) + conventional western medicine (CWM)" was the most effective way in increasing total efficiency ratio. "Huange capsule (HE) + CWM" was the most effective method in decreasing prostate volume. "Qianliesutong capsule (QLST) + CWM" was the most effective approach in decreasing residure volume. "Xialiqi capsule (XLQ) + CWM" was the most effective way in increasing maximum urinary flow rate. "Longbisu capsule (LBS) + CWM" was the most effective method in decreasing international prostate symptom score (IPSS). To reduce the adverse reactions, "HE + CWM" has the best efficacy. Considering both drug efficacy and safety, "Ningmitai capsule (NMT) + CWM" would be the most ideal choice.
Based on NMA, JKSQ, HE, QLST, XLQ, LBS, NMT plus CWM have been proved to possess the highest probability of being the best therapy. Due to the limitations of this study, these results should be confirmed through detailed randomized controlled trials.
https://www.crd.york.ac.uk/prospero/, Identifier, CRD42023484071.
本文旨在通过基于频率的网状Meta分析，评估各种口服中成药治疗良性前列腺增生（BPH）的疗效和安全性差异。
研究人员检索了以下数据库：科学网、PubMed、医学文摘数据库（Embase）、考克兰图书馆、中国知网（CNKI）、中国生物医学文献服务系统（SinoMed）、万方数据知识服务平台和中国科技期刊数据库（维普）。此外，研究人员收集了自数据库建立至2024年7月1日期间，所有关于口服中成药以及治疗良性前列腺增生的单方制剂和单味药的随机对照试验（RCT）。在两名研究人员独立筛选文献、提取数据并评估纳入研究的偏倚风险后，使用Stata 16.0软件进行网状Meta分析。
纳入了72项RCT，涉及15种口服中成药，共7800例患者。网状Meta分析表明，“金匮肾气胶囊（JKSQ）+ 常规西药（CWM）”是提高总有效率最有效的方法。“癃闭舒胶囊（HE）+ CWM”是缩小前列腺体积最有效的方法。“前列舒通胶囊（QLST）+ CWM”是减少残余尿量最有效的方法。“夏荔芪胶囊（XLQ）+ CWM”是提高最大尿流率最有效的方法。“龙必舒胶囊（LBS）+ CWM”是降低国际前列腺症状评分（IPSS）最有效的方法。为减少不良反应，“HE + CWM”疗效最佳。综合考虑药物疗效和安全性，“宁泌泰胶囊（NMT）+ CWM”将是最理想的选择。
基于网状Meta分析，已证明JKSQ、HE、QLST、XLQ、LBS、NMT加CWM最有可能是最佳治疗方法。由于本研究的局限性，这些结果应通过详细的随机对照试验加以证实。
